Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry

被引:44
作者
Flarakos, J
Luo, W
Aman, M
Svinarov, D
Gerber, N
Vouros, P
机构
[1] Northeastern Univ, Barnett Inst, Dept Chem & Chem Biol, Boston, MA 02115 USA
[2] Ohio State Univ, Dept Pharmacol, Columbus, OH 43210 USA
[3] Med Univ Sophia, BG-1431 Sofia, Bulgaria
关键词
column switching; validation; risperidone; hydroxyrisperidone;
D O I
10.1016/j.chroma.2003.10.138
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A robust and validated LC-MS-MS quantitative method, using column switching and mutiple reaction monitoring was developed for the analysis of risperidone (RIS) and 9-hydroxyrisperidone in human plasma and saliva. The analytical range was 1-100 ng/ml. The method used 25 mul of sample precipitated with 75 mul of acetonitrile containing internal standard (R068808). Analyses were conducted on a PE Sciex API-III + triple quadrupole mass spectrometer fitted with a Turbo IonSpray source. The method was validated for human plasma using EDTA as the anticoagulant and cross-validated to heparinized human plasma and saliva. The recoveries of risperidone and 9-hydroxyrisperidone were 90-93 and 89-93%, respectively. The validated method was applied to clinical samples to study risperidone and 9-hydroxyrisperidone concentrations in plasma and saliva. Risperidone and 9-hydroxyrisperidone appear in the saliva of patients treated with risperidone. Their detection/quantification in saliva provides evidence for recent adherence with therapy. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:175 / 183
页数:9
相关论文
共 28 条
[1]  
Aravagiri M, 2000, J MASS SPECTROM, V35, P718, DOI 10.1002/1096-9888(200006)35:6<718::AID-JMS999>3.0.CO
[2]  
2-O
[3]   FLOW-DEPENDENT SALIVARY PRIMIDONE LEVELS IN EPILEPTIC CHILDREN [J].
BARTELS, H ;
GUNTHER, E ;
WALLIS, S .
EPILEPSIA, 1979, 20 (04) :431-436
[4]   Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia [J].
Chouinard, G ;
Kopala, L ;
Labelle, A ;
Beauclair, L ;
Johnson, SV ;
Singh, KI .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1998, 43 (10) :1018-1025
[5]  
CHOUINARD G, 1993, CAN J PSYCHIAT, V38, P89
[6]  
FANG J, 1999, NAUNYNSCHMIEDENBERGS, P359
[7]  
HART BJ, 1987, METHOD FIND EXP CLIN, V2, P127
[8]  
HEESWIJK RP, 2001, THER DRUG MONIT, V23, P255
[9]  
HORNING MG, 1977, CLIN CHEM, V23, P157
[10]   PHARMACOKINETICS OF THE NOVEL ANTIPSYCHOTIC AGENT RISPERIDONE AND THE PROLACTIN RESPONSE IN HEALTHY-SUBJECTS [J].
HUANG, ML ;
VANPEER, A ;
WOESTENBORGHS, R ;
DECOSTER, R ;
HEYKANTS, J ;
JANSEN, AAI ;
ZYLICZ, Z ;
VISSCHER, HW ;
JONKMAN, JHG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) :257-268